Introduction: Ovarian stimulation can be performed in early follicular phase or after pretreatment with OCPs. The aim of this study is to know if OCPs prior to ovarian stimulation improve the results in an IVF cycle. Material and methods: Retrospective case-control study. We included 132 patients (aged 18-40 years) undergoing two consecutive IVF-ICSI cycles (264 cycles). One cycle was initiated without pretreatment and the other after pretreatment with dienogest 2 mg/etinylestradiol 0.03 mg. The dose and type of gonadotropins used was adjusted according to age, body mass index and antral follicle count. During ovarian stimulation, serial ultrasound and analytical controls were performed until the day of ovulation induction and puncture programming. Results: There were statistically significant differences in gestation rates with a higher number of pregnancies in the OCPs group (37.18% vs. 13.95%, p=0.005). The live newborn rate was higher in the group of patients prepared with OCPs (30.77% vs. 5.81%, p=0.005). Total days of stimulation was lower in the OCPs group (8.50 vs. 9.13, p=0.000). There were no statistically significant differences in the total number of oocytes retrieved, metaphase II oocytes or embryo quality. Conclusions: the use of OCPs can be considered as a pre-treatment in an IVF cycle since it allows us to plan ovarian stimulation without worsening the live birth rate.
| Published in | American Journal of Clinical and Experimental Medicine (Volume 10, Issue 3) |
| DOI | 10.11648/j.ajcem.20221003.12 |
| Page(s) | 74-78 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Oral Contraceptive Pill, Live Birth Rate, Controlled Ovarian Stimulation, IVF, ICSI
| [1] | Pandian Z, Bhattacharya S, Vale L, Templeton A. In vitro fertilisation for unexplained subfertility. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD003357.pub2]. |
| [2] | Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod Oxf Engl 2011; 26: 2593–2597. |
| [3] | Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. In Cochrane Gynaecology and Fertility Group, editor. Cochrane Database Syst Rev [Internet] 2016; Available from. http://doi.wiley.com/10.1002/14651858.CD001750.pub4. |
| [4] | Toftager M, Bogstad J, Bryndorf T, L. ssl K, Rosk. r J, Holland T, Pr. torius L, Zedeler A, Nilas L, Pinborg A. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod 2016; 31: 1253–1264. |
| [5] | Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2012; 18 (1): 73–91. |
| [6] | Block E. Quantitative morphological investigations of the follicular system in women; variations in the different phases of the sexual cycle. Acta Endocrinol (Copenh). 1951; 8 (1): 33–54. |
| [7] | Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier J. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Contraception 1984; 29 (4): 305–18. |
| [8] | Gonen Y, Jacobson W, Casper RF. Gonadotropin suppression with oral contraceptives before in vitro fertilization. Fertility and Sterility 1990; 53 (2): 282–7. |
| [9] | Barmat LI, Chantilis SJ, Hurst BS, Dickey RP. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertil Steril 2005; 83: 321–330. |
| [10] | Huirne JAF, van LACD, Donnez J, Pirard C, Homburg R, Schats R, McDonnell J, Lambalk CB. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reprod Biomed Online 2006b; 13: 235–245. |
| [11] | Garcia-Velasco JA, Fatemi HM. To pill or not to pill in GnRH antagonist cycles: that is the question! Reprod Biomed Online 2015; 30: 39–42. |
| [12] | Garcia-Velasco JA, Bermejo A, Ruiz F, Martinez-Salazar J, Requena A, Pellicer A. Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertil Steril 2011; 96: 590–593. |
| [13] | Griesinger G, Kolibianakis EM, Venetis C, Diedrich K, Tarlatzis B. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril 2010; 94: 2382–2384. |
| [14] | Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropinreleasing hormone analogues and on subsequent implantation and pregnancy rates. Fertil Steril 1998; 70: 1063–1069. |
| [15] | Fukuda M, Fukuda K, Yding Andersen C, Byskov AG. Does anovulation induced by oral contraceptives favor pregnancy during the following two menstrual cycles? Fertil Steril 2000; 73: 742–747. |
| [16] | Griesinger G, Venetis CA, Marx T, Diedrich K, Tarlatzis BC, Kolibianakis EM. Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil Steril 2008; 90: 1055–1063. |
| [17] | Farquhar C, Rombauts L, Kremer JA, Lethaby A, Ayeleke RO. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. In Cochrane Gynaecology and Fertility Group, editor. Cochrane Database Syst Rev [Internet] 2017; Available from. http://doi.wiley.com/10.1002/14651858.CD006109.pub3. |
| [18] | Blockeel, C., 2012. Estradiol valerate pretreatment in GnRHantagonist cycles. Reprod. Biomed. Online 25, 223–224. |
| [19] | Guivarc’h-Levêque, A., Homer, L., Arvis, P., Broux, P. L., Moy, L., Priou, G., Vialard, J., Colleu, D., Dewailly, D., 2011. Programming in vitro fertilization retrievals during working days after a gonadotropin-releasing hormone antagonist protocol with estrogen pretreatment: does the length of exposure to estradiol impact on controlled ovarian hyperstimulation outcomes? Fertil. Steril. 96, 872–876. |
| [20] | Hauzman, E. E., Zapata, A., Bermejo, A., Iglesias, C., Pellicer, A., Garcia-Velasco, J. A., 2013. Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial. Reprod. Biol. Endocrinol. 28, 96. |
APA Style
Guijarro Guedes Jesús, Santana Suárez Alejandra, Álvarez Sánchez Mónica, Roldán Gutiérrez Lourdes, Benítez Castillo Nelda, et al. (2022). Optimization of Ovarian Stimulation After Preparation with Oral Hormonal Contraceptives. American Journal of Clinical and Experimental Medicine, 10(3), 74-78. https://doi.org/10.11648/j.ajcem.20221003.12
ACS Style
Guijarro Guedes Jesús; Santana Suárez Alejandra; Álvarez Sánchez Mónica; Roldán Gutiérrez Lourdes; Benítez Castillo Nelda, et al. Optimization of Ovarian Stimulation After Preparation with Oral Hormonal Contraceptives. Am. J. Clin. Exp. Med. 2022, 10(3), 74-78. doi: 10.11648/j.ajcem.20221003.12
AMA Style
Guijarro Guedes Jesús, Santana Suárez Alejandra, Álvarez Sánchez Mónica, Roldán Gutiérrez Lourdes, Benítez Castillo Nelda, et al. Optimization of Ovarian Stimulation After Preparation with Oral Hormonal Contraceptives. Am J Clin Exp Med. 2022;10(3):74-78. doi: 10.11648/j.ajcem.20221003.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajcem.20221003.12,
author = {Guijarro Guedes Jesús and Santana Suárez Alejandra and Álvarez Sánchez Mónica and Roldán Gutiérrez Lourdes and Benítez Castillo Nelda and Tabares Concepción José and Sánchez Sánchez Victoria and Martin Martínez Alicia},
title = {Optimization of Ovarian Stimulation After Preparation with Oral Hormonal Contraceptives},
journal = {American Journal of Clinical and Experimental Medicine},
volume = {10},
number = {3},
pages = {74-78},
doi = {10.11648/j.ajcem.20221003.12},
url = {https://doi.org/10.11648/j.ajcem.20221003.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20221003.12},
abstract = {Introduction: Ovarian stimulation can be performed in early follicular phase or after pretreatment with OCPs. The aim of this study is to know if OCPs prior to ovarian stimulation improve the results in an IVF cycle. Material and methods: Retrospective case-control study. We included 132 patients (aged 18-40 years) undergoing two consecutive IVF-ICSI cycles (264 cycles). One cycle was initiated without pretreatment and the other after pretreatment with dienogest 2 mg/etinylestradiol 0.03 mg. The dose and type of gonadotropins used was adjusted according to age, body mass index and antral follicle count. During ovarian stimulation, serial ultrasound and analytical controls were performed until the day of ovulation induction and puncture programming. Results: There were statistically significant differences in gestation rates with a higher number of pregnancies in the OCPs group (37.18% vs. 13.95%, p=0.005). The live newborn rate was higher in the group of patients prepared with OCPs (30.77% vs. 5.81%, p=0.005). Total days of stimulation was lower in the OCPs group (8.50 vs. 9.13, p=0.000). There were no statistically significant differences in the total number of oocytes retrieved, metaphase II oocytes or embryo quality. Conclusions: the use of OCPs can be considered as a pre-treatment in an IVF cycle since it allows us to plan ovarian stimulation without worsening the live birth rate.},
year = {2022}
}
TY - JOUR T1 - Optimization of Ovarian Stimulation After Preparation with Oral Hormonal Contraceptives AU - Guijarro Guedes Jesús AU - Santana Suárez Alejandra AU - Álvarez Sánchez Mónica AU - Roldán Gutiérrez Lourdes AU - Benítez Castillo Nelda AU - Tabares Concepción José AU - Sánchez Sánchez Victoria AU - Martin Martínez Alicia Y1 - 2022/05/12 PY - 2022 N1 - https://doi.org/10.11648/j.ajcem.20221003.12 DO - 10.11648/j.ajcem.20221003.12 T2 - American Journal of Clinical and Experimental Medicine JF - American Journal of Clinical and Experimental Medicine JO - American Journal of Clinical and Experimental Medicine SP - 74 EP - 78 PB - Science Publishing Group SN - 2330-8133 UR - https://doi.org/10.11648/j.ajcem.20221003.12 AB - Introduction: Ovarian stimulation can be performed in early follicular phase or after pretreatment with OCPs. The aim of this study is to know if OCPs prior to ovarian stimulation improve the results in an IVF cycle. Material and methods: Retrospective case-control study. We included 132 patients (aged 18-40 years) undergoing two consecutive IVF-ICSI cycles (264 cycles). One cycle was initiated without pretreatment and the other after pretreatment with dienogest 2 mg/etinylestradiol 0.03 mg. The dose and type of gonadotropins used was adjusted according to age, body mass index and antral follicle count. During ovarian stimulation, serial ultrasound and analytical controls were performed until the day of ovulation induction and puncture programming. Results: There were statistically significant differences in gestation rates with a higher number of pregnancies in the OCPs group (37.18% vs. 13.95%, p=0.005). The live newborn rate was higher in the group of patients prepared with OCPs (30.77% vs. 5.81%, p=0.005). Total days of stimulation was lower in the OCPs group (8.50 vs. 9.13, p=0.000). There were no statistically significant differences in the total number of oocytes retrieved, metaphase II oocytes or embryo quality. Conclusions: the use of OCPs can be considered as a pre-treatment in an IVF cycle since it allows us to plan ovarian stimulation without worsening the live birth rate. VL - 10 IS - 3 ER -
Information
Email: